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Lethal mutagenesis is a new antiviral therapy based on increasing the mutation rate by 
using mutagenic base and nucleoside analogues whose molecular mechanisms are not 
fully understood. Most of the research has been conducted on animal RNA viruses in 
cell culture and, to a lesser extent, in vivo. There is experimental evidence supporting 
the model of lethal defection for lethal mutagenesis of RNA viruses. In this model, viral 
genomes with a low degree of mutation and low specific infectivity, termed 
"defectors", exert an interfering activity leading to virus loss. Lethal mutagenesis of 
plant viruses has not been addressed yet despite being excellent in vivo model systems 
that develop systemic infections, undergo rapid bottlenecks and pose no ethical issues. 
Here, we address lethal mutagenesis in vivo of Tobacco mosaic virus (TMV), a single-
stranded positive RNA virus of 6.4 Kb. Nicotiana tabacum plants cultured in vitro were 
treated with 25, 50 and 100 µg/ml of the base analogue 5-fluorouracil (FU) and 24 h 
later were inoculated with 50 lesion forming units (lfu) of TMV. We analyzed the 
infectivity, viral load and mutant spectra of viral populations after 5 and 10 days of 
treatment, as well as of populations that went 10 days of treatment followed by 21 
days of ex vitro growth in the absence of FU. 
The results show that TMV infectivity decreases when treated with 50 and 100 µg/ml 
FU for 10 days. TMV mutagenized populations grown without FU reach infectivity 
values higher than untreated populations. Predominant mutations in FU-treated 
populations with decreased infectivity at 10 dpi are U→C, A→G and G→A transitions, 
which are expected due to the action of FU. TMV replication is not affected by FU at 
any dose and there are no imbalances of ribonucleotide triphosphate pools measured 
by HPLC. No differences in mutation frequencies and Shannon Entropies between 
control and FU-treated populations with declined infectivity were found. However, we 
did found a dose-dependent decrease of specific infectivity in FU-treated populations, 
but not in untreated samples, as well as dominance of molecules with a low degree of 
mutation. Specific infectivity recovered to control levels after 21 days of growth 
without the analogue. Altogether, our results suggest that TMV defector molecules 
mediate the decrease in TMV infectivity. This is the first report that addresses the 
molecular basis of lethal defection in vivo using an RNA plant virus.  
 
